


5



CLAIMS

1. A compound of the formula

10




where R_1 is of the formulae




- 5 R_2 is $-R_4$, $-O-R_4$, $-O-S(O)_2-R_4$, $-NR_4R_5$, $R_4-(CH_2)_b-NH(C=X)-(CH_2)_c-$, $R_4-(CH_2)_b-O(C=O)NH-(CH_2)_c-(C=O)NH-$, $R_4-(C=O)NH-(C=O)NH-$, $-(CH_2)_b-NH(C=X)-(CH_2)_c-R_4$, $R_4-(CH_2)_b-O(C=O)-(CH_2)_c-$, $-(CH_2)_b-O(C=O)-(CH_2)_c-R_4$, $-NH(C=X)NH-R_4$, $R_4-O(C=O)O-$, $-O(C=O)NH-R_4$, $R_4-O(C=O)NH-$, $-(CH_2)_b-(C=O)-(CH_2)_c-R_4$, $-NH-S(O)_2-R_4$, $-C(OH)R_4R_5$, $-CH(OH)-R_4$, $-(C=O)-NR_4R_5$, $-CN$, $-NO_2$, substituted C_1 to C_6 alkyl, substituted or unsubstituted C_1 to C_6 alkenyl, or substituted or unsubstituted C_1 to C_6 alkynyl, said substituted moieties substituted with a moiety of the formulae $-R_4$, $-R_4R_5$, $-O-R_4$, or $-S(O)_d-R_4$;

R_3 is hydrogen, $CH_3OCH_2CH_2$, C_1 to C_6 alkyl, C_1 to C_6 alkylaryl, or aryl;


R_4 and R_5 are each independently



XV



XVI




XVII

- 15 hydrogen, $-CF_3$, C_1 to C_6 alkyl, C_1 to C_6 alkylaryl, with the proviso that when R_2 is $-R_4$ or $-OR_4$, R_4 is not hydrogen or C_1 to C_6 alkyl;

R_6 , R_7 , R_8 , R_9 , R_{10} , R_{11} , R_{12} , R_{13} , R_{14} , R_{15} , R_{16} , R_{17} , and R_{18} are each independently H, halogen, $-CF_3$, $-(C=O)R_{20}$, $-CN$, $-OR_{20}$, $-NR_{20}R_{21}$, $-NR_{20}SO_2R_{22}$, $-N=C-N(CH_3)_2$, $-N_{20}CO_2R_{22}$, $-S(O)_6R_{20}$, $-SO_2NR_{20}R_{21}$, $-NO_2$, aryl, C_1 to C_6 alkylaryl,

- 5 $-(C=O)OR_{20}$, $-(C=O)NR_{20}R_{21}$, C_1 to C_6 alkyl, C_1 to C_6 alkenyl, and C_1 to C_6 alkynyl;
 R_6 and R_7 , R_7 and R_8 , R_8 and R_9 , R_9 and R_{10} , R_{11} and R_{12} , R_{12} and R_{13} , R_{13} and R_{14} , R_{15} and R_{16} , R_{16} and R_{17} , and R_{17} and R_{18} may be taken together to form a five-to-seven-membered alkyl ring, a six-membered aryl ring, a five to seven membered heteroalkyl ring having one heteroatom of N, O, or S, or a five-to six-membered heteroaryl ring have 1 or 2 heteroatoms of N, O, or S;
10 R_{19} is hydrogen or C_1 to C_3 alkyl;
 R_{20} and R_{21} are each independently hydrogen, C_1 to C_6 alkyl, aryl, or C_1 to C_6 alkylaryl, or may be taken together to form a C_4 to C_7 alkyl ring;
 R_{22} is C_1 to C_6 alkyl, aryl, or C_1 to C_6 alkylaryl;
15 A, B, D, E, and F are each independently C or N;
G, I, J, and K are each independently C, N, O, S, or (C=O), with the proviso that there is at most one of O, (C=O), or S per ring;
L and Z are each independently C or N;
M is C, N, or (C-24O);
20 X is O or S;
a is 0, 1 or 2;
e is 0, 1 or 2;
d is 0, 1, or 2;
b and c are each independently 0, 1, 2, 3, 4, 5, or 6, with b+c being at most 6;
25 a broken line indicates the presence optionally of a double bond and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C_1 to C_4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C_1 to C_4 alkoxy, and pharmaceutically acceptable salts thereof.
30
2. The compound of claim 1, wherein R_1 is formula II; R_2 is $-R_4$, $-OR_4$, $R_4-(CH_2)_b-NH(C=X)-(CH_2)_c-$, or $-(CH_2)_b-NH(C=O)-(CH_2)_c-R_4$; R_3 is hydrogen or C_1 to C_6 alkyl; R_4 is formula XV or formula XVII; A, B, D, E, and F are each independently C or N; R_6 , R_7 , R_8 , R_9 , R_{10} , R_{15} , R_{16} , R_{17} , R_{18} , and R_{19} are each independently hydrogen, halogen, -CN, or $-OR_{20}$; and R_{20} is C_1 to C_6 alkyl.
35
3. The compound of claim 1, wherein R_1 is formula III; R_2 is $-R_4$, $-OR_4$, $R_4-(CH_2)_b-NH(C=X)-(CH_2)_c-$, or $-(CH_2)_b-NH(C=O)-(CH_2)_c-R_4$; R_4 is formula XV or formula XVII; R_3 is hydrogen or C_1 to C_6 alkyl; A, B, D, E, and F are each independently C or N; R_6 , R_7 , R_8 , R_9 , R_{10} , R_{15} , R_{16} , R_{17} , R_{18} , and R_{19} are each independently hydrogen, halogen, -CN, or $-OR_{20}$; and R_{20} is C_1 to C_6 alkyl.
40

5 4. The compound of claim 1, wherein R₁ is



15 R₂ is -R₄, -OR₄, R₄-(CH₂)_b-NH(C=X)-(CH₂)_c-, or -(CH₂)_b-NH(C=O)-(CH₂)_c-R₄; R₃ is hydrogen or C₁ to C₆ alkyl; R₄ is formula XV or formula XVII; A, B, D, E, and F are each independently C or N; R₆, R₇, R₈, R₉, R₁₀, R₁₅, R₁₆, R₁₇, R₁₈, and R₁₉ are each independently hydrogen, halogen, -CN, or -OR₂₀; and R₂₀ is C₁ to C₆ alkyl.

20 5. The compound of claim 1, wherein R₁ is formula II, formula III, or formula IV; R₂ is -R₄; R₃ is hydrogen or C₁ to C₆ alkyl; R₄ is formula XVII; G, I, J, and K are each independently C, N, or O; L is C; R₁₁, R₁₂, R₁₃, and R₁₄ are each independently hydrogen, C₁ to C₆ alkyl, or C₁ to C₆ alkylaryl.

25 6. The compound of claim 1, said compound being selected from:
7-(Imidazo[4,5-b]pyridin-1-yl)-1-(1-methylpyrrolidin-3-yl)naphthalene;
7-(4-Chlorobenzamido)-1-(pyrrolidin-2-(R)-ylmethyl)naphthalene;
2-[8-(4-Methylpiperazin-1-yl)naphthalen-2-yloxy]nicotinonitrile;
1-(4-Methylpiperazin-1-yl)-7-pyrimidin-5-yl)naphthalene;
7-(5-Cyanopyridin-3-yl)-1-(4-methylpiperazin-1-yl)naphthalene;
1-(Piperazin-1-yl)-7-(pyrimidin-5-yl)naphthalene;
7-(4-Chlorobenzamido)-1-(4-methylpiperazin-1-yl)naphthalene;
7-(3-Methoxyphenyl)-1-(4-methylpiperazin-1-yl)naphthalene;
7-(Imidazo[4,5-b]pyridin-1-yl)-1-(4-methylpiperazin-1-yl)naphthalene;
30 8-(4-Methylpiperazin-1-yl)naphthalene-2-carboxylic acid 4-chlorobenzylamide;
7-(4-Methoxyphenyl)-1-(4-methylpiperazin-1-yl)-naphthalene;
7-Pyrimidin-2-yloxy-1-(4-methylpiperazin-1-yl)naphthalene;
7-(Benzimidazol-1-yl)-1-(4-methylpiperazin-1-yl)naphthalene; and
8-(1-Methylpiperidin-4-yl)naphthalene-2-carboxylic acid 4-chlorobenzylamide.

35 7. A pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, Alzheimer's disease, and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising an amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically
40 acceptable carrier.

- 5 R_2 is (Methyl)₃Sn- or (Butyl)₃Sn-; R_3 is hydrogen, C₁ to C₆ alkyl, C₁ to C₆ alkylaryl, or
aryl; a is 0, 1, or 2; and a broken line indicates the presence optionally of a double bond
and the above aryl groups and the aryl moieties of the above alkylaryl groups are
independently selected from phenyl and substituted phenyl, wherein said substituted
phenyl may be substituted with one to three groups selected from C₁ to C₄ alkyl,
10 halogen, hydroxy, cyano, carboxamido, nitro, and C₁ to C₄ alkoxy.